




scentech[®] MEDICAL

Breath Diagnostics Technologies



Company Status - august 2022

Forward-looking Information

This presentation does not constitute an offer to purchase shares in Nextgen Biomed Ltd. and Scent Medical Technologies Ltd., hereinafter: "Scentech" or "the Company" or an invitation to receive such offers, and is intended to merely provide general information, which by nature is incomplete, and as part of the effort to provide information on Scentech to institutional investors and analysts and/or third parties.

This presentation is intended to provide a general overview for your convenience. It cannot take the place of the tests published for public release, which include the full company information, prior to making any decision on investing in the Company shares.

This presentation contains forward-looking information as defined in the Securities Law, 1968. This information contains, inter alia, forecasts, goals and estimates relating to future events and/or issues that might not materialize and/or which are not under the Company's exclusive control.

Forward-looking information is not a proven fact and is by its very nature subject to significant risks of non-materialization. The said information is neither certain nor can it be accurately forecast, and its materialization or lack of materialization may be influenced, inter alia, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors impacting the Company that cannot be forecast and which are not under the Company's control.

In view of the above, the readers of this presentation are reminded that the actual results and achievements of the Company in the future are likely to substantially differ from those presented in the forward-looking information included in this presentation, and that the Company's assumptions regarding completion of the initiative are not certain, and possibly might not be completed in the current format or at all, in light of the fact that completion of the initiative is subject to completion of the conditions and milestones that have yet to reach fruition and/or be completed. Accordingly, completion of the venture is not certain and depends on all the above taking place and this might not materialize or might do so only in part or differently than what is stated above, and thus is considered forward-looking information as defined in the Securities Law.

Moreover, the forecasts and estimates of the forward-looking information are based on information and data available to the Company at the time of publishing the presentation, and the Company does not undertake to update and/or change each forecast and/or estimate in order to reflect events and/or circumstances that might occur after the presentation's date of publication.

About Scentech Medical Technologies Ltd.

Scentech is a trailblazing company, specializing in identifying various pathogen-specific volatile organic chemical compounds (biomarkers). The unique compounds identified undergo a process of verification, are registered as patents and are then ready for commercialization.

At the same time, the Company is developing unique diagnostic systems to identify the biomarkers via real-time chemical analysis of exhaled air.

The Company started out by mapping biomarkers and developing systems for identifying various types of cancer and infectious diseases such as TB and hospital-acquired infections. At an early stage, following the outbreak of the coronavirus (COVID-19), the Company was quick to recognize the need for the rapid and non-invasive detection of those infected with the coronavirus as well as carriers. Accordingly, the Company decided to focus its efforts on the daunting challenge of coronavirus detection.

Throughout 2020, the Company established a cutting-edge laboratory for mapping biomarkers based on VOCs (volatile organic compounds). In parallel, the Company conducted a number of clinical trials in hospitals throughout Israel, attended by thousands of trial subjects in order to map out the coronavirus biomarkers.

During the research, the Company successfully identified unique biomarkers for the coronavirus.



scentech[®] MEDICAL

Screening and Diagnostic Tests

The Current Situation

Today, there are no screening tests for most diseases, and the only screening tests that do exist, such as mammography, the PAP smear test and the fecal occult blood test (FOBT) have turned out to be problematic, and their ability to detect the diseases for which they are designed leaves much to be desired.

Diagnostic tests to detect and identify diseases are currently conducted at expensive laboratories, they usually require a skilled team to carry them out and are considerably time-consuming, making them costly.

A considerable percentage of the tests conducted, both screening and diagnostic, are invasive, painful, and under certain circumstances potentially dangerous (for example, X-rays can cause cancer).

As a result of these starting data, the number of screening tests is on the decline. In addition, due to these obstacles, the public health authorities refrain from carrying out frequent diagnostic tests both in developed and developing countries, where cost and accessibility pose an even more significant barrier.



The Immediate Threat – the Coronavirus

The World Health Organization (WHO) and the Centers for Disease Control & Prevention (CDC) in the USA have declared that the coronavirus will continue to present a tangible threat to our existence for a number of years.

The ability to locate outbreaks and mutations at the local, national and global level (“heat maps”) is an essential and critical tool in the fight to prevent the spread of pandemics as a whole and of the coronavirus in particular.

The existing array of tests provides only a partial picture that hampers our ability to accurately identify the true state of morbidity in real time.

The technology which Scentech has developed provides the requisite tool for the fight against the coronavirus, by conducting a large number of tests per day and real-time monitoring of the pandemic's spread, as changes in the biomarkers examined during the test can be indicative of a new mutation.



Breath Tests – the Future of Diagnostics

Advantages of breath tests:

- ▶ A rapid, accurate and non-invasive test providing an immediate result.
- ▶ Low cost (only a few dollars per test).
Can be frequently repeated and without any medical limitations.
- ▶ One test enables identification of a large number of diseases at early stages.
- ▶ Enables ongoing health monitoring and provides warning of pathological changes indicative of the onset of a disease.
- ▶ It is based on a cloud database of biomarkers that grows and is updated, leading to a constantly developing ability to identify additional diseases without the need for any hardware changes.
- ▶ The test is carried out by an automatic sampling process thus obviating the need for skilled workers.

Scentech Medical's current objective:

A non-invasive breath test for the rapid identification of COVID-19 based on the Company's biomarkers

scentech MEDICAL



The VOX System

- ▶ The VOX system designed by Scentech Medical, based on clinical trials conducted with some of the leading medical institutions in Israel and abroad, is the first automatic test to fulfill the vision of breath tests.
- ▶ The VOX system is the first one to offer a rapid test for identifying both people infected with COVID-19 and carriers of the virus, based on biomarkers.
- ▶ The VOX system is an automatic system, enabling sampling of subjects and conducting on-the-spot chemical analysis without the need to send samples to a central lab, and all that is required is a disposable mouthpiece, replaced during each test.
- ▶ The VOX system is the first and only commercial system for identifying diseases in exhaled breath, enabling it to identify a number of diseases in one test.




scentech[®] MEDICAL

Biomarkers Sampled


At the Meir Hospital and Shamir (Assaf Harofeh) Medical Center:

Forest plot of Normalized Area Meir & Shamir subset



Independent Verification of the Mapped Biomarkers:

Analysis of the biomarkers by cross-checking with cycle time (Ct) in a PCR test





Detection of Diseases by a Simple Breath Test

scentech[®] MEDICAL

Scentech – the Way Ahead

Scentech Medical, which established the leading cutting-edge laboratory in the world for identifying biomarkers in exhaled breath, has begun to map biomarkers for additional diseases, such as different types of cancer and various infections, specifically those commonly acquired in hospitals that are resistant to antibiotics.

The Company's aim is to turn the breath tests into a leading diagnostic tool available in every doctor's clinic, enabling the identification of diseases in their early stages, monitoring treatment efficacy along with the subjects' health.

The Company is already developing the next generation of its diagnostic systems, with a strong focus on speed, accuracy and operational simplicity.



Joint Ventures

Scentech Medical signed an MoU for collaboration with LSRI or Life Science Research Israel Ltd. (the commercial arm of the Israel Institute for Biological Research), in which it was agreed that the parties would engage in extensive cooperation, including work to verify the identity of the biomarkers, validation of the composition and structure of the compounds located by Scentech for detecting the coronavirus, and joint research for the development and verification of additional biomarkers. This joint venture entails the development of a joint working plan, executing a pilot, a trial run and analysis of 300 high-resolution, mass spectra sample analyses. In addition, verification of the results obtained during the joint work will be carried out via joint laboratory analysis.

Scentech Medical is conducting clinical trials in Shamir Medical Center (Assaf Harofeh) after receiving Helsinki approval for each of the studies. Among the studies being conducted: a clinical study for the Identification of COVID-19 infected persons using breath test, a clinical study for identification of Pfizer vaccination human response.

Scentech Medical is also conducting several clinical trials in Pedah Poria Medical center, including COVID-19 biomarkers validation and additional respiratory infectious disease biomarkers mapping.



scentech MEDICAL

Patents and Regulatory Approval

The Company received authorization for its main patent and has begun to register it worldwide: <https://patents.google.com/patent/WO2020089923A1>.

The Company has filed a number of provisional applications and will continue towards approving them as patents during the coming year.

On August 31, 2021, the Company received ISO 13485 approval for development of a medical device.

The Company is in close contact with the Ministry of Health to authorize the VOX system as soon as possible.

The Company is involved in a concomitant effort to obtain FDA approval for the system as well as EU CE approval.



Revenue Model

The Company's revenue model is based on the sale of the VOX systems almost at cost price while charging per test (Nespresso model).

The Company has completed development of the automatic sampling system and is in the final stages before "design freeze."

The Company is in close contact with the Ministry of Health to authorize the VOX system.

The Company is in contact with a number of distributors and will commence distribution as soon as it receives the regulatory approval in those countries where the systems are to be marketed.

The Company's revenue model is based on a fixed price of only a few dollars per test. The Company expects its revenue from use of the devices to reach tens of millions of USD already in the first year.

Integration of the additional systems under development by the Company, which considerably reduce the test time, is expected to significantly increase the Company's profits, once these systems are operational.



scentech[®] MEDICAL



management board



Ran Tal

CEO

Ran is a CPA with extensive managerial, operational and financial experience. He served as EVP & CFO of a worldwide retailer as well as CFO of Several Apax owned companies, and in his last role served as CFO of a Company owned by Canaan Partners & Axa Ventures (and several additional minority holdings investors) . Over the years Ran gained vast experience in both mature industrial and tech based companies, with local and international operations.



Prof Shmuel Shapira

CTO

Shmuel Shapira MD MPH (Colonel Res.) is a physician and Full Professor of Medical Administration at the Hebrew University Faculty of Medicine. Professor Shapira was for 8 years until 2021 the Director General of the Israel Institute for Biological Research and Chair of the Board of Life Science Research Israel. Past Deputy Director General of the Hadassah Medical Organization, Director (founder) of the Military Tract of the Hebrew University Faculty of Medicine, and former Director of the Hebrew University Hadassah School of Public Health. Professor Shapira serves as an authority on R&D administration, innovation, Risk Management, terror medicine and trauma.

Entrepreneurs



Harel Hershtik

Founder and VP Strategy & Technology

Harel is one of the founders of Scentech Medical. He has a successful track record mapping breath biomarkers and developing systems for detecting chemicals at extremely low concentrations. In addition, Harel has broad knowledge in the areas of chemical analysis, ion mobility, breath analytics, metabolomics, and genetic expression diagnostics. Over the years he has developed algorithms for identifying biomarkers, designed revolutionary non-radioactive ion sources, and designed specialized instruments needed for breath-based diagnostics.



Drew Morris

Founder and Director

Drew is an expert in the areas of metabolomics, breath analysis, and genetic expression diagnostics. He served on multiple advisory panels addressing the planning for pandemics and global health threats. He continues to be an outspoken advocate for the need for rapid diagnostic tools based on genetic expression, as a means to contain the spread of infectious diseases and improve health outcomes.

The Scientific Council



Dr. Andre Ofek

Senior Consultant

Dr. Andre Ofek is an expert in plastic surgery and serves as the Deputy Director of the Plastic Surgery Department at the Shamir (Assaf Harofeh) Medical Center. He deals with a variety of esthetic and reconstructive surgery, such as carcinoma removal (melanoma, basal cell carcinoma, and squamous cell carcinoma removal), Mohs surgery, and lipoma removal (benign tumors of fat tissue).



Prof. Nati Keller

Senior Consultant

Prof. Nati Keller is an expert in laboratory medicine and clinical microbiology at the Sheba Medical Center, Tel Hashomer. Prof. Keller serves as the Head of the Laboratory Division and Director of the Department of Clinical Microbiology at the Sheba Medical Center. Prof. Keller is a member of the Israel Society for Infectious Diseases and an expert in the epidemiology of infectious diseases, resistance to antibiotics, and fungal infections in immunocompromised patients.



Prof. Zeev Rotstein

Chair of the Council

Prof. Zeev Rotstein has served in the past as CEO and Director of the Sheba Medical Center, Director-General of the Hadassah Medical Center and Chairman of the Health Basket Committee. Rotstein is a consultant cardiologist with an MA in Health System Management from the Faculty of Management at Tel Aviv University and has an expert diploma in Health System Management. He teaches at the Faculty of Management at Tel Aviv University, lecturing on epidemiology, preventive medicine, occupational medicine, the health systems in Israel, healthcare policy and economic issues involved in managing health systems, as well as risk management in medicine.

Directors



Yaniv Chevron

Director

Yaniv combines extensive financial expertise with significant experience in the capital market. He was Chief Strategy Officer and Director of Analysis at Excellence Investment House, managing over USD 35 billion in assets. In addition, Yaniv was an economics lecturer for a decade at the College of Management Academic Studies (COLMAN). In recent years, Yaniv has accumulated a wealth of experience in leading “growth companies”, including an extended period in Silicon Valley. Yaniv is an alumnus of the lucrative NFX “accelerator program” and has an MA in Economics from Tel Aviv University.



Dr. Keren-Or Amar

Director

Dr. Amar has held a number of management positions in the Biomed and Pharma Industries. Dr. Amar is currently the VP for Business Development at Yissum, the Hebrew University's technology transfer company. She was CEO of the ShizimXL medical devices accelerator, and both founded and managed the R&D Authority at the Shaare Zedek Medical Center. Dr. Amar earned her Ph.D. at Bar-Ilan University, completed post-doctorals studies at the Hebrew University, Jerusalem, and holds a BSc and MSc from the Technion Israel Institute of Technology. In addition, Dr. Amar also has an MA in Law from Bar-Ilan University.

The Senior Scientific Team



Dr. Natalie Dror

VP Clinical & Regulatory Affairs

Dr. Natalie Dror has extensive leadership experience in medical device product management including R&D, pre-clinical studies, clinical studies design, the establishment of regulatory strategies, and submissions to regulatory authorities worldwide.

Dr. Dror received her MSc in Medicine, and her PhD in Biotechnology from the Technion - Israel Institute of Technology



Dr. Regina Sinelnikov

VP Analytical Chemistry

Dr. Regina brings her drive and passion for meaningful science to her role as the Analytical Laboratory Manager. She holds a PhD in Materials Chemistry from the University of Alberta and a BSc in Chemistry and Computer Science from Western University. Dr. Sinelnikov honed her analytical skills as a researcher at the Analytical Laboratory of the Israeli Air Force, where she specialized in the identification and



Konstantin Tartakovsky

Senior Analytical Research Chemist

Konstantin has over 20 years of analytical experience as the head of the Analytical Laboratory in the Israeli Air Force. Konstantin's expert command of numerous analytical tools served him well in aircraft failure investigations, air quality analyses, and applied research at the IAF. He developed multiple methods for the quality assurance and forensic analysis of non-metallic materials. The state-of-the-art laboratory under his command boasted unique capabilities, some of which were developed by him in-house. Konstantin obtained his BSc in Chemistry and MSc in Medical Science from Tel-Aviv University.

The Founders' Vision – in a Nutshell

A non-invasive test enabling diagnosis of a large number of diseases in their early stages, in the case of infectious diseases – the accurate identification of the pathogen to a level enabling antibiotic compatibility without waiting 3 days for the culture results, considered to be the Holy Grail of the world of diagnostics.

When each metabolic process, and each healthy or unhealthy cell (such as cancer) or invading cells (such as bacteria or virus) produce thousands of different substances at any given moment, such a test has been considered impossible.

In recent years, it has emerged that each metabolic process, whether of (both healthy and unhealthy) body cells or invading cells (pathogens), have a unique chemical signature composed of a number of organic compounds. In many cases, a part of that signature includes volatile organic gases that eventually find their way into the air we breathe. Scentech Medical is the leading company in the world in the field of mapping volatile organic gas-based unique chemical signatures (biomarkers), and it won't be long before the Company offers a non-invasive breath test enabling diagnosis of a growing number of diseases, along with monitoring of an individual's state of health.

Scentech Medical is engaged in a relentless effort to turn this vision into an available and accurate test for everyone, to ensure a safer and healthier future for us and our children.



scentech[®] MEDICAL



Thank You

scentech[®] MEDICAL
Breath Diagnostics Technologies

Company Status - august 2022